SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ABOS reported Third Quarter 2026 results. The price and volatility reaction is pending.
ABOSearnings

Earnings reactions, page 12

Acumen Pharmaceuticals, Inc. (ABOS) Q3 FY2026 earnings

October 26, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and marketable securities totaled $78.6 million as of September 30, 2026.
  • Research and development (R&D) expenses were $21.1 million for the quarter ended September 30, 2026.
  • General and administrative (G&A) expenses were $4.7 million for the quarter ended September 30, 2026.
  • Loss from operations was $25.8 million for the quarter ended September 30, 2026.
  • Net loss was $25.4 million for the quarter ended September 30, 2026.

Guidance

  • Cash is expected to support current clinical and operational activities into early 2027.
  • The Company expects to report topline results from ALTITUDE-AD in November 2026.
  • The Company is targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →